November 25, 2019
1 min read
Save

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 1, single center, open-label study to establish a safe dose (ie, number of cells/kg) of autologous iC9.GD2.CAR.IL-15 T-cells in pediatric patients with relapsed or refractory neuroblastoma.